Y. Arman Et Al. , "Can the Serum Endocan Level Be Used as a Biomarker to Predict Subclinical Atherosclerosis in Patients with Prediabetes?," Arquivos brasileiros de cardiologia , vol.119, pp.544-550, 2022
Arman, Y. Et Al. 2022. Can the Serum Endocan Level Be Used as a Biomarker to Predict Subclinical Atherosclerosis in Patients with Prediabetes?. Arquivos brasileiros de cardiologia , vol.119 , 544-550.
Arman, Y., Atici, A., Altun, O., Sarikaya, R., Yoldemir, S. A., Akarsu, M., ... Kutlu, O.(2022). Can the Serum Endocan Level Be Used as a Biomarker to Predict Subclinical Atherosclerosis in Patients with Prediabetes?. Arquivos brasileiros de cardiologia , vol.119, 544-550.
Arman, Yucel Et Al. "Can the Serum Endocan Level Be Used as a Biomarker to Predict Subclinical Atherosclerosis in Patients with Prediabetes?," Arquivos brasileiros de cardiologia , vol.119, 544-550, 2022
Arman, Yucel Et Al. "Can the Serum Endocan Level Be Used as a Biomarker to Predict Subclinical Atherosclerosis in Patients with Prediabetes?." Arquivos brasileiros de cardiologia , vol.119, pp.544-550, 2022
Arman, Y. Et Al. (2022) . "Can the Serum Endocan Level Be Used as a Biomarker to Predict Subclinical Atherosclerosis in Patients with Prediabetes?." Arquivos brasileiros de cardiologia , vol.119, pp.544-550.
@article{article, author={Yucel Arman Et Al. }, title={Can the Serum Endocan Level Be Used as a Biomarker to Predict Subclinical Atherosclerosis in Patients with Prediabetes?}, journal={Arquivos brasileiros de cardiologia}, year=2022, pages={544-550} }